Verve plans to advance a second PCSK9 program and the ANGPTL3 candidate into clinical testing next year. According to Evans Beam would have made an optin decision on its own regarding the Verve programs possibly by next year. But Lilly expressed interest in getting more involved spurring Beam to choose to sell its rights